68 Ga-FAPI-04 PET/CT and 18 F-FDG PET/CT in Metastatic Papillary Renal Cell Cancer.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 May 2023
01 May 2023
Historique:
medline:
5
4
2023
pubmed:
9
2
2023
entrez:
8
2
2023
Statut:
ppublish
Résumé
Papillary renal cell cancer is a rare malignancy with limited treatment options in the advanced stage of the disease. We present the case of a 62-year-old man with progressive left-sided papillary renal cell carcinoma who underwent 68 Ga-FAPI (fibroblast activated protein inhibitor)-04 and 18 F-FDG PET/CT imaging. 68 Ga-FAPI-04 PET/CT demonstrated variable FAP expression in all metastatic lesions detected by 18 F-FDG PET/CT, including multiple lymph nodes, bone, and thyroid. This case highlights that FAP-targeted imaging can be a promising modality for diagnostic and theranostic use in papillary renal cell carcinoma.
Identifiants
pubmed: 36754359
doi: 10.1097/RLU.0000000000004587
pii: 00003072-202305000-00031
doi:
Substances chimiques
68Ga-FAPI
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Gallium-68
98B30EPP5S
Gallium Radioisotopes
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e223-e224Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin . 2019;69:7–34.
Deng J, Li L, Xia H, et al. A comparison of the prognosis of papillary and clear cell renal cell carcinoma: evidence from a meta-analysis. Medicine . 2019;98:e16309.
Hou G, Zhao D, Jiang Y, et al. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma. Cancer Imaging . 2021;21:1–9.
Ueno D, Yao M, Tateishi U, et al. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer . 2012;12:1–8.
Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw . 2022;20:71–90.
Muselaers S, Erdem S, Bertolo R, et al. PSMA PET/CT in renal cell carcinoma: an overview of current literature. J Clin Med . 2022;11:1829.
Has Simsek D, Civan C, Erdem S, et al. Complementary role of 68 Ga-prostate-specific membrane antigen and 18 F-FDG PET/CT for evaluation of metastases and treatment response in renal cell carcinoma. Clin Nucl Med . 2021;46:579–581.
Oflas M, Ozluk Y, Sanli O, et al. 68 Ga-PSMA uptake patterns of clear cell renal carcinoma across different histopathological subtypes. Clin Nucl Med . 2022;47:e45–e46.
Zschäbitz S, Erlmeier F, Stöhr C, et al. Expression of prostate-specific membrane antigen (PSMA) in papillary renal cell carcinoma—overview and report on a large multicenter cohort. J Cancer . 2022;13:1706–1712.
Kuyumcu S, Kovan B, Sanli Y, et al. Safety of fibroblast activation protein–targeted radionuclide therapy by a low-dose dosimetric approach using 177 Lu-FAPI04. Clin Nucl Med . 2021;46:641–646.
Kuyumcu S, Sanli Y, Subramaniam RM. Fibroblast activated protein inhibitor (FAPI) PET/CT: cancer diagnosis and management. Front Oncol . 2021;11:758958.
Kratochwil C, Flechsig P, Lindner T, et al. 68 Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med . 2019;60:801–805.
Pang Y, Wei J, Shang Q, et al. 68 Ga-fibroblast activation protein inhibitor, a promising radiopharmaceutical in PET/CT to detect the primary and metastatic lesions of chromophobe renal cell carcinoma. Clin Nucl Med . 2021;46:177–179.
Xie F, Fu L, Zhou W. Superiority of 68 Ga-FAPI-04 in delineation of soft tissue and liver metastases in chromophobe renal cell carcinoma for restaging. Clin Nucl Med . 2022;47:e758–e759.